AGIOS PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
AGIOS PHARMACEUTICALS, INC. (AGIO) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $0 as of 2017-03-31, per its 10-Q filed 2017-05-04.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2017-05-04
- 2017-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $0.00.
- 2016-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $0.00.
- 2016-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $0.00.
- 2016-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value |
|---|---|
| 2017-03-31 | $0.00 10-Q · filed 2017-05-04 |
| 2016-12-31 | $0.00 10-K · filed 2017-02-16 |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-03 |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-08 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-09 |
| 2015-12-31 | $0.00 10-K · filed 2017-02-16 |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-06 |
| 2015-06-30 | $0.00 10-Q · filed 2015-08-07 |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-11 |
| 2014-12-31 | $0.00 10-K · filed 2016-02-26 |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-07 |
| 2014-06-30 | $0.00 10-Q · filed 2014-08-07 |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-09 |
| 2013-12-31 | $0.00 10-K · filed 2015-02-24 |
| 2013-09-30 | $0.00 10-Q · filed 2014-11-07 |
| 2013-06-30 | $0.00 10-Q · filed 2014-08-07 |
| 2013-03-31 | $0.00 10-Q · filed 2014-05-09 |
| 2012-12-31 | $0.00 10-K · filed 2014-03-18 |
| 2012-09-30 | $0.00 10-Q · filed 2013-11-07 |
| 2012-06-30 | $0.00 10-Q · filed 2013-09-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |